Nuwellis Shifts Focus from REVERSE-HF Trial to Outpatient Heart Failure Growth
Minneapolis, Thursday, 17 July 2025.
Nuwellis ends its REVERSE-HF clinical trial to pivot resources toward expanding outpatient heart failure care, expecting to save $4.0 million over 2.5 years.
Strategic Redirection
Nuwellis, Inc. (NASDAQ: NUWE), a medical device company renowned for its innovative cardiovascular solutions, has strategically decided to terminate its REVERSE-HF clinical trial as of July 17, 2025. The trial, which began enrolling patients in 2022, was assessing the efficacy of ultrafiltration compared to intravenous loop diuretic therapy for managing fluid in hospitalized heart failure patients [1].
Focus on Outpatient Care
The decision to terminate the REVERSE-HF trial is aimed at reallocating resources to enhance the company’s growth in outpatient heart failure care. This pivot comes in response to increasing demand and interest in Nuwellis’ ultrafiltration therapy within hospital-based outpatient programs [1].
Economic Impact and Future Plans
By terminating the trial, Nuwellis anticipates saving approximately $4.0 million over the next 2.5 years, which is expected to bolster the company’s financial health and operational focus [1]. The company plans to collaborate with key stakeholders to determine the statistical value of the existing REVERSE-HF data, ensuring that previous efforts contribute to future advancements [1].
Market Performance Context
The announcement coincides with notable movements in the stock market, as the healthcare sector has shown exceptional performance amidst broader economic dynamics. Notably, on July 16, 2025, the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all reported gains, supported by robust performances in sectors including healthcare and real estate, despite ongoing inflation concerns [2].
Nuwellis’ Market Response
Following the patent approval of its medical technology in the U.S., Nuwellis experienced a significant surge in its stock price, rising nearly 130% recently. This increase underscores investor confidence in the strategic shift and the company’s future potential [2].